PathoQuest, a pioneer in the quality control of biologics using Next-Generation Sequencing (NGS), today announced the closing of a financing round up to €15M. This funding leverages the NGS technology in a proprietary approach to assess the viral safety and genetic characterization of biologics. It will support the development of PathoQuest’s US site (Wayne, PA), the expansion of the portfolio of NGS-based quality control tests and will accelerate its growth and market share worldwide.

Written by

WITH US, YOU CANCO-INVEST IN DEEP TECH STARTUPS

Verve's investor network

With annual investments of EUR 60-70 mio, we belong to the top 10% most active startup investors in Europe. We therefore get you into competitive financing rounds alongside other world-class venture capital funds.

We empower you to build your individual portfolio.

Sign up to receive our regular newsletter and learn about investing in technologies that are changing the world.

Privacy Preference Center